Goodwin Procter advised Aditum Bio and its new portfolio company, Celexor Bio, in an in-licensing transaction with Inmagene Biopharmaceuticals. Celexor Bio is being formed in connection…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
